Enlivex Therapeutics Ltd.
ENLV | TA
Overview
Corporate Details
- ISIN(s):
- IL0011319527
- LEI:
- Country:
- Israel
- Address:
- Weizmann Science Park, 14 Einstein St., 7403618 Ness Ziona
- Website:
- https://enlivex.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Enlivex Therapeutics Ltd. is a clinical-stage biopharmaceutical company specializing in macrophage reprogramming immunotherapy. The company's core focus is the development of Allocetra™, a universal, off-the-shelf cell therapy platform designed to restore immune balance by reprogramming macrophages into a homeostatic state. Enlivex is evaluating Allocetra™ for the treatment of a range of acute and chronic inflammatory diseases, with clinical trials underway for indications such as sepsis and osteoarthritis. The therapy is designed for flexible administration, either through systemic intravenous infusion or targeted local injections, and has shown a positive safety profile in clinical studies.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Enlivex Therapeutics Ltd..
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-18 17:12 |
Foreign Filer Report
Presentation- PHASE IIA TOPLINE RESULTS
|
English | 3.8 MB | |
| 2025-08-18 17:12 |
Foreign Filer Report
Presentation- PHASE IIA TOPLINE RESULTS
|
English | 36.4 KB | |
| 2025-08-18 16:59 |
Foreign Filer Report
Form 6-K- Positive Topline Data From Multi-Country, Randomized, Controlled, Pha…
|
English | 156.5 KB | |
| 2025-08-18 16:59 |
Foreign Filer Report
Form 6-K- Positive Topline Data From Multi-Country, Randomized, Controlled, Pha…
|
English | 36.4 KB | |
| 2025-08-14 17:54 |
Foreign Filer Report
Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Ost…
|
English | 173.8 KB | |
| 2025-08-14 17:54 |
Foreign Filer Report
Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Ost…
|
English | 36.3 KB | |
| 2025-07-28 17:42 |
Foreign Filer Report
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II T…
|
English | 149.8 KB | |
| 2025-07-28 17:42 |
Foreign Filer Report
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II T…
|
English | 36.3 KB | |
| 2025-05-31 01:44 |
Foreign Filer Report
Financial statements as of a March 31, 2025
|
English | 271.6 KB | |
| 2025-05-31 01:44 |
Foreign Filer Report
Financial statements as of a March 31, 2025
|
English | 36.5 KB | |
| 2025-05-14 01:32 |
Prospectus
Renewal of ATM plan
|
English | 545.8 KB | |
| 2025-05-14 01:32 |
Foreign Filer Report
Renewal of ATM plan
|
English | 36.3 KB | |
| 2025-05-03 02:24 |
Registration Form
FORM F-3-prospectus in one or more offerings
|
English | 617.9 KB | |
| 2025-05-03 02:24 |
Foreign Filer Report
FORM F-3-prospectus in one or more offerings
|
English | 36.3 KB | |
| 2025-05-01 02:02 |
Foreign Filer Report
20F For the fiscal year ended December 31, 2024
|
English | 1.7 MB |
Automate Your Workflow. Get a real-time feed of all Enlivex Therapeutics Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Enlivex Therapeutics Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
